Journal for ImmunoTherapy of Cancer (Nov 2021)

358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial

  • Peter Oppelt,
  • Jingxia Liu,
  • Douglas Adkins,
  • Jessica Ley,
  • Kevin Palka,
  • Miriam Jacobs

DOI
https://doi.org/10.1136/jitc-2021-SITC2021.358
Journal volume & issue
Vol. 9, no. Suppl 2

Abstract

Read online

No abstracts available.